Aim: To determine whether admission screening for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) influences decisions about empiric antibiotic coverage, and whether having screening results leads to more appropriate empiric therapy choices.
Bharara et al. (Sun,) studied this question.